10 results about "Autistic disorders" patented technology

FIELD: neurology; psychiatry.SUBSTANCE: used as a non-pharmacological therapy for autism spectrum disorders in children. The method includes a set of procedures: interval hypoxic-hyperoxic training (HHT), hyperbaric oxygenation and ozone therapy. HHT consists of alternating inhalations of a hypoxic mixture with an oxygen content of 9 to 16 vol.% and a hyperoxic mixture with an oxygen content of 32 to 40 vol.% for a total duration of 45-50 minutes under the control of cardiovascular system parameters. Hyperbaric oxygenation is performed in a pressure chamber under a pressure of 1.3 atmospheres of 100% oxygen mixture, flow of 10 liters per minute, for 45 minutes using a mask. Ozone therapy is performed by rectal insufflation with an ozone-oxygen mixture with an ozone concentration of 85 μg / ml in a volume of 20–30 ml or by intravenous administration of a physiological solution enriched with ozone with an ozone concentration of 85 μg / ml at a rate of 200 ml per 100 ml of physiological solution. The procedures are carried out daily for 12 days.EFFECT: method is effective and has a positive impact on the patient’s condition.1 cl, 1 dwg, 3 ex

The present invention is directed to the use of antiviral agents, in particular valomaciclovir stearate and its polymorph Form A, as well as H2G (omaciclovir) to treat multiple sclerosis in combination with other agents, as well as the use of these agents to treat diseases and conditions such as chronic mononucleosis, long COVID, chronic fatigue syndrome, fibromyalgia, Crohn's disease, ulcerative colitis, rheumatoid arthritis, systemic lupus erythematosus, Graves' disease, Alzheimer's disease, mesial temporal lobe seizures, Epstein-Barr-virus-linked autism, or an Epstein-Barr-virus-linked cancer.

The invention discloses a method for improving autism behaviors through Npas4 expression and overexpression in a cat chat syndrome model, and belongs to the technical field of animal model construction. Selecting SD wild rats and CdCS model rats, and normally feeding and breeding the rats; the method comprises the following steps: measuring the protein concentration by adopting a BCA method, then carrying out Western Blot, then carrying out brain stereotactic injection, and finally carrying out behavioral testing. According to the invention, a CdCS rat model is established by using a CRISPR-Cas9 technology, and the model shows cognitive and social behavior disorders and medial prefrontal cortex (mPFC) neuron dendritic abnormality; in addition, an abnormally expressed gene is found in the model mouse, the research focuses on Npas4, and a new insight is possibly provided for disease treatment.

The present application relates to the cross field of target detection and emotion recognition, and particularly relates to a facial expression recognition method for autistic children based on deep learning. The method comprises the following steps: embedding a three-dimensional attention (Tri-Attention) after a C3k2 module of a YOLOv11 backbone network to model the interaction relationship among height, width and channel dimensions in parallel, and enhancing the response to key expression regions such as eyes and corners of the mouth; introducing the three-dimensional attention (Tri-Attention) again at the multi-scale feature output end of the neck network to realize effective positioning of small-scale faces in a complex background and suppression of background noise; training and verifying the YOLOv11-TA model by using a public data set and a self-built autistic children data set respectively, and outputting the detection frame and expression category of each face; and comparing various indexes of the original YOLOv11 and the YOLOv11-TA on multiple data sets, and actually verifying that the method significantly improves the accuracy and robustness of the expression recognition of autistic children.

A targeted acupuncture treatment method for children with autism belongs to the field of medical care, and comprises a sound induction ear acupuncture method, a long-acting eye stimulation opposite pressing acupuncture method and a liver-spleen-kidney simultaneous acupuncture method. The system can improve the core symptoms of the autistic children (3-12 years old), such as not listening to instructions, eye contact parallax, inattention, diet singleness, emotion awareness, hyperactivity and the like, realizes targeted intervention through multi-module collaborative acupuncture, and is suitable for pediatrics of medical institutions, children rehabilitation centers and professional acupuncture clinics.

A pharmacological method for treating the expressive language deficit in an autistic human child or adult is provided. A therapeutically effective dose of a succinimide anticonvulsant, e.g., ethosuximide, methsuximide, phensuximide, or a pharmaceutically acceptable salt thereof, is administered to a patient suffering from expressive language deficit, preferably over an extended period, e.g., six months or longer. Language gains are retained even after treatment is discontinued.

The present invention relates to dosing regimens and methods of using LY3154207, also described as 2-(2,6-dichlorophenyl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2 (1H)-yllethanone, and / or pharmaceutical compositions thereof, for treatment of dopaminergic central nervous system disorders. Dopaminergic CNS disorders of the present dosing regimen methods include Parkinson's Disease, Alzheimer's Disease, Lewy body dementia (LBD), Vascular Dementia, Schizophrenia, ADHD, Depression, Autism, chronic musculoskeletal pain, fibromyalgia, cognitive impairment disorders, sleep disorders, excessive daytime sleepiness, narcolepsy, shift work disorder, traumatic brain injury, chronic traumatic encephalopathy, obesity and appetite regulation, mood disorders, lethargy, apathy, and addiction disorders.

The invention discloses an infantile autism family psychological intervention system and an infantile autism family psychological intervention method. Comprising a family psychological state dynamic monitoring module, a multiple psychological therapy technology integration module, a physiological collaborative rehabilitation intervention module, a family interaction mode optimization module, a personalized intervention scheme generation module, an intervention effect real-time evaluation and dynamic adjustment module, a family support resource integration module and a child behavior observation and feedback module. By monitoring the family psychology and interaction state in real time, various treatment technologies and resources are integrated, and a personalized intervention scheme is generated. The method comprises the steps of baseline evaluation, scheme making, intervention implementation, dynamic adjustment, follow-up visit consolidation and the like, focuses on improvement of the psychological state of parents and a family interaction mode, creates a supportive rehabilitation environment for autistic children, and has a remarkable intervention effect through practice verification.

The subject matter described herein includes methods and systems for predicting and preventing negative behaviors with learning and AI algorithms. According to one method, physiological data of a user is measured. For example, using sensors located on the user. A stress level of the user is determined based on the measured physiological data. An intervention is then determined for adjusting the stress level of the user in response to the stress level being at least one of outside or nearing outside of a baseline range of the user. According to one system, at least one sensor measures physiological data of a user. An analysis device, such as a mobile device or remote server, determines a stress level of the user based on the measured physiological data and determines an intervention for adjusting the stress level of the user in response to the stress level being outside or nearing outside of a baseline range of the user.

Provided is a Bifidobacterium lactis. The Bifidobacterium lactis is Bifidobacterium animalis subsp. lactis BL-11, and the preservation number of the Bifidobacterium animalis subsp. lactis BL-11 is CGMCC No. 20847. The provided Bifidobacterium animalis subsp. lactis can improve intestine metabolism disorder and normalize the composition of intestine microbiome so as to improve height, suppresses obesity, promote infant and youth physical development and mental development, and prevent and treat mental disorders, said mental disorders including anxiety, depression, attention-deficit / hyperactivity disorder, autism, schizophrenia, hepatic encephalopathy, anorexia, Tourette syndrome, and Asperger syndrome.